Sorafenib combined with conventional strategy as salvage therapy for refractory central nervous system leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048055

Enrollment

Unknown

Registered

2021-06-29

Start date

2017-03-11

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central nervous system leukemia

Interventions

1:sorafenib combined with conventional strategy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-65 years; 2. acute leukemia; 3. ECOG performance status of 0-2; 4. refractory CNSL; 5. excluding the following exclusion criteria.

Exclusion criteria

Exclusion criteria: 1. CML with blast crisis; 2. Philadelphia chromosome positive ALL; 3. intolerance to sorafenib previously; 4. active GVHD; 5. uncontrolled infections(6)other conditions not suitable for this study determined by the researcher.

Design outcomes

Primary

Measure	Time frame
remission rate;survival;	—

Countries

China

Contacts

Public ContactQifa Liu

Nanfang Hospital, Southern Medical University

liuqifa628@163.com+86 13602791429

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026